GTS Securities’s ImmunityBio IBRX Stock Holding History

GTS Securities’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$118K	Sell	13,465 -720	-5%	-$5.45K	﹤0.01%	1254
2026 Q1	$109K	Buy	+14,185	New	+$97.1K	﹤0.01%	1420
2024 Q2	–	Sell	-20,467	Closed	-$135K	–	4089
2024 Q1	$110K	Buy	+20,467	New	+$92.7K	﹤0.01%	3507

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GTS Securities's IBRX Position: Q2 2026 in Review

GTS Securities reduced its ImmunityBio (IBRX) stake by 5.1% in Q2 2026, selling an estimated $5.45K and leaving 13,465 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #1254.

GTS Securities first reported a position in IBRX in Q1 2024 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

GTS Securities held 13,465 shares of ImmunityBio worth $118K as of Q2 2026.
GTS Securities sold 720 ImmunityBio shares in Q2 2026, an estimated $5.45K.
ImmunityBio made up ﹤0.01% of GTS Securities's portfolio in Q2 2026, its #1254 holding.
GTS Securities first reported a position in ImmunityBio in Q1 2024 and has held it in 3 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.